DANIEL PARK: Open Payments
NPI 1124201801 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$822 in 38 payments from 13 companies in 2025. Trend: 2023 $839 · 2024 $100 · 2025 $822
Food & beverage: $822
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $280 |
| Neurocrine BioSciences, Inc. | 6 | $146 |
| E.R. Squibb & Sons, L.L.C. | 4 | $105 |
| Alkermes, Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Sage Therapeutics, LLC | 2 | $33 |
| Indivior Inc. | 1 | $32 |
| ABBVIE INC. | 2 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: INGREZZA, ABILIFY MAINTENA, REXULTI, COBENFY, ABILIFY ASIMTUFII, ARISTADA, TRINTELLIX, FANAPT.
Industry payments across NV — which companies pay providers there.
